Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 4/20 | 0.32 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25411360 | 0.86 | DGAT1 (0.32) | ACACBABHD6FAAHMGLLITGB3 | |
| SCHEMBL30503535 | 0.86 | DGAT1 (0.32) | ACACBABHD6FAAHMGLLITGB3 | |
| SCHEMBL25411482 | 0.86 | GPR119 (0.42) | ACACBABHD6FAAHMGLLDGAT1 | |
| SCHEMBL25410957 | 0.85 | FFAR4 (0.31) | FFAR4ACACBABHD6FAAHMGLL | |
| SCHEMBL25434328 | 0.85 | ACACB (0.34) | FFAR4ACACBABHD6FAAHMGLL | |
| SCHEMBL26631338 | 0.80 | ACACB (0.34) | ACACBABHD6FAAHMGLLITGB3 | |
| SCHEMBL26631421 | 0.79 | FFAR4 (0.32) | FFAR4ABHD6FAAHMGLLITGB3 | |
| SCHEMBL30503541 | 0.78 | DGAT1 (0.37) | ACACBDGAT1 | |
| SCHEMBL26631319 | 0.78 | DGAT1 (0.37) | ACACBDGAT1 | |
| SCHEMBL30503578 | 0.77 | HCRTR1 (0.31) | FFAR4ABHD6FAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| CN-116323557-A | Cyclobutylamide monoacylglycerol lipase modulators | 詹森药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | FFAR4 130/4885ACACB 61/4885ABHD6 25/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | FFAR4 125/4885ACACB 60/4885ABHD6 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.